Experience in the Use of Valdoxan (agomelatine) in the Treatment of Depression in Patients with Dyscirculatory Encephalopathy

Objective – to study the efficacy and tolerance of agomelatine (Valdoxan) in mild depressive states in patients with chronic cerebral ischemia (CCI). Materials and methods. The study included 33 patients (23 women, 10 men, mean age 54.5 years). Grade I CCI was diagnosed in 12 patients (36.4%) and grade II in 21 (63.6%). All patients had single depressive episodes of mild severity. Diagnoses of affective and cognitive impairments were based on the Hamilton Rating Scale for Depression (HRDS-17), the Hospital Anxiety and Depression Scale (HADS), the Vein Nocturnal Sleep Questionnaire, the Mini Mental State Examination (MMSE), the Mini-Cog test, the Montreal Cognitive Assessment Scale, the physician's Clinical Global Impression scale for assessment of the severity and dynamics of illness (CGI-S, CGI-I), and the Patients' Global Impression of Change Scale (PGIC). Investigations were performed at prescription of agent and at 2, 4, and 8 weeks of treatment. All patients received agomelatine (Valdoxan) once daily at a dose of 25 mg. Results and conclusions. Use of agomelatine led to improvements in sleep from week 2, with reductions in anxiety symptoms at six weeks, and reductions in depressive symptomatology at eight weeks of treatment. In addition, treatment with agomelatine produced improvements in cognitive functions in the patients. No patient experienced any treatment side effects. The study results demonstrated high antidepressant activity in the treatment of mild depressive disorders in patients with CCI, with a balanced spectrum of actions in relation to symptoms of anxiety, depression, and dyssomnia, along with positive actions on cognitive functions, allowing the use of agomelatine in the treatment of patients with CCI to be recommended.

from Physiology via xlomafota13 on Inoreader http://ift.tt/2eImhjw
via IFTTT